Your session is about to expire
← Back to Search
Lorigerlimab for Advanced Solid Tumors
Study Summary
This trial is testing a new drug, lorigerlimab, to see if it is safe and effective in treating patients with advanced solid tumors. The trial will first determine the maximum tolerated dose of the drug, and then expand to test its efficacy in specific tumor types.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Frequently Asked Questions
Are there any remaining openings for participants in this experiment?
"Evidently, this trial is not currently searching for participants. Initially posted on December 12th 2018 and last updated October 10th 2022, the study has yet to begin recruiting individuals. Nevertheless, there are 2,968 other trials that remain open for enrolment at present."
What is the geographical extent of this experiment?
"Beth Israel Deaconess Medical Center in Boston, Massachusetts; The Sarah Cannon Research Institute / Tennessee Oncology in Nashville, Tennessee; and UPMC Pinnacle - Ortenzio Cancer Centre (OCC) in Mechanicsburg, Nebraska are the main sites for this trial. Additionally 16 other medical centres are involved."
Has the FDA accepted MGD019 for public use?
"The safety of MGD019 stands at a 1, as this is an initial Phase 1 trial with limited clinical evidence validating its efficacy and security."
Share this study with friends
Copy Link
Messenger